AzTrials
AzTrials

Myopia ProgressionPhase 3NCT07535749

The Effect of Myopia-Control Contact Lenses in New Zealand Chinese Children

A Phase 3 study testing MiSight Contact Lenses (CooperVision) and Albiliti 1-Day (Johnson and Johnson, VisionCare) in people with Myopia Progression, run by Aston University at 1 site in New Zealand.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

The study will employ a randomized, controlled, investigator-masked paired-eye comparison design to evaluate the effects of two myopia-control contact lenses-MiSight 1 Day and Abiliti 1-Day-in New Zealand Chinese children. Read more about this study

Who is it for?
Ages 7 to 11 years
Conditions the study is for
Myopia Progression
What is being tested?
MiSight Contact Lenses (CooperVision) and Albiliti 1-Day (Johnson and Johnson, VisionCare)
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
66 participants
Where
1 siteNew Zealand
Study dates
21 Mar 2026to 30 May 2027
Phase
Phase 3
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 7 to 11 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Spherical refractive error between -1.00D and -4.50D
  • Astigmatism of ≤1.00D
  • No history of orthokeratology or atropine use
  • No ocular diseases or surgical history

Who cannot join

  • o No ocular diseases or surgical history

Trial locations and contacts

1 site in 1 country.

New Zealand1 site
  • Auckland Myopia Clinic

    Auckland, 1052

Other trials in New Zealand

About this study

The study will employ a randomized, controlled, investigator-masked paired-eye comparison design to evaluate the effects of two myopia-control contact lenses-MiSight 1 Day and Abiliti 1-Day-in New Zealand Chinese children.

The study duration will be 12 months, with assessments conducted at baseline, 2 weeks, 3 months, 6 months and 12 months.

The clinical research will be conducted at the Auckland Myopia Clinic (New Zealand) and will follow a standard clinical routine for children with early myopia, the only difference being the randomizing of the MiSight and Abiliti contact lenses between the two eyes of the participants.

Read the detailed description
  1. Study Design The study will employ a randomized, controlled, investigator-masked paired-eye comparison design to evaluate the effects of two myopia-control contact lenses-MiSight 1 Day and Abiliti 1-Day-in New Zealand Chinese children. The study duration will be 6 months, with assessments conducted at baseline, 2 weeks, 3 months, and 6 months. The clinical research will be conducted at the Auckland Myopia Clinic (New Zealand) and will follow a standard clinical routine for children with early myopia, the only difference being the randomizing of the MiSight and Abiliti contact lenses between the two eyes of the participants.
  2. Participants 2.1 Recruitment and Eligibility Criteria • Participants: 53-66 New Zealand Chinese children aged 7-11 years.
  • Inclusion criteria:
  • Spherical refractive error between -1.00D and -4.50D
  • Astigmatism of ≤1.00D
  • No history of orthokeratology or atropine use
  • No ocular diseases or surgical history
  • Recruitment will be through social media, patient referrals, and school outreach. 2.2 Sample Size A similar study, of soft contact lenses with novel ring focus for controlling myopia progression, based their sample size on treatment efficacy of >0.08 mm (standard deviation [SD]: 0.10) in axial elongation from baseline and >0.20 D (SD: 0.32) in change of spherical equivalent cycloplegic autorefraction (SECAR) from baseline at 26 weeks. Controlling the 2-sided type I error rate at the 0.05 level, the researchers found that sample size of 40 subjects per group would yield >80% power for detecting treatment efficacy. To estimate the sample size for the present study, a priori power analysis was performed using the program G∗Power (version 3.1.9.7). For a 95% confidence interval (Z = 1.96) and a study power of 80%, and controlling the 2-sided type I error rate at the 0.05 level, the estimated sample size is 53 pairs of eyes (53 subjects), as each participant contributes both eyes to the study. Providing for a 20% dropout rate, the recruitment target becomes 66 participants.
  1. Interventions Each participant will wear:
  • MiSight 1 Day dual-focus lens in one eye (2.00D defocus)
  • Abiliti 1-Day lens in the contralateral eye (7.00D defocus)
  1. Data Collection Methods 4.1 Baseline and Follow-up Assessments
  • Cycloplegic refraction (CycloRx) and retinoscopy (Ret) will be conducted.
  • Axial length will be measured using MYAH optical biometry.
  • Ocular surface assessments:
  • Children Dry Eye Questionnaire (CDEQ) responses
  • Non-invasive Tear break-up time (NIBUT) using MYAH's dry eye function
  • Ocular Protection Index (OPI) calculation using MYAH
  • Corneal staining assessment via MYAH corneal staining and slit lamp fluorescein
  • Lissamine green conjunctiva staining (graded and recorded) 4.2 Timepoints for Data Collection
  • Baseline (0 months): Cycloplegic refraction, axial length, CDEQ, NIBUT, OPI, corneal staining.
  • 2 weeks: Axial length, ocular surface assessments, dry eye symptoms.
  • 3 months: Axial length, ocular surface assessments, dry eye symptoms.
  • 6 months: Final assessments of axial length, ocular surface health, and dry eye symptoms.
  1. Outcome Measures
  2. Myopia-control efficacy: Comparison of axial length elongation between the two contact lenses.
  3. Ocular surface health:
  • CDEQ responses
  • NIBUT measurements
  • OPI calculation
  • Corneal staining severity Should one lens slow the development of myopia more than the other, the lenses will be reversed at the end of the study.
  1. Parent Perception Questionnaire

A structured questionnaire will be administered at baseline and at 6 months to assess parents' expectations and perceptions of the contact lenses as a myopia treatment. Topics covered include:

  • Baseline Questionnaire: Motivations, barriers, facilitators, and expectations for contact lens treatment.
  • Follow-up Questionnaire: Changes in attitudes, satisfaction with treatment compared to initial expectations, and future adherence.
  1. Ethical Considerations The study will comply with optometric ethical standards. Participants and parents will provide informed consent. Data confidentiality will be maintained, and the study will be subject to institutional ethics review.
  2. Study Personnel The study will be investigator-masked and conducted by two paediatric optometrists,who each have extensive experience in myopia management. Both have conducted over 800 paediatric myopia exams.
  3. Statistical Analysis Data will be analysed using SPSS software. Axial length changes will be compared between paired eyes using paired t-tests. Dry eye symptoms and corneal staining scores will be analysed using a repeated measures ANOVA.
Being tested
MiSight Contact Lenses (CooperVision), Albiliti 1-Day (Johnson and Johnson, VisionCare)
Keywords
myopia control, contact lenses

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • MiSight Contact Lenses (CooperVision)Device

    Myopia Control Contact Lens

  • Albiliti 1-Day (Johnson and Johnson, VisionCare)Device

    Myopia Control Contact Lens

Study groups in NCT07535749
Study groupRoleWhat they receive
MiSight Contact LensActive comparatorCommercially available myopia control contact lens
Receives: Device: MiSight Contact Lenses (CooperVision)
Abiliti 1-DayActive comparatorCommercially available myopia control contact lens
Receives: Device: Albiliti 1-Day (Johnson and Johnson, VisionCare)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Mean Spherical Equivalent Cycloplegic Refraction

    The dioptric refractive error as determined by retinoscopy following cycloplegic refraction

    Measured: Baseline, 2 weeks, 3 months, 6 months, 12 months

  2. Axial length

    Ocular biometry measured with Myah biometer

    Measured: Baseline, 2 weeks, 3 months, 6 months, 12 months

Secondary outcomes (5)
  1. Children Dry Eye Questionnaire (CDEQ) response

    Total score derived from the Children Dry Eye Questionnaire (CDEQ)

    Measured: Baseline, 2 weeks, 3 months, 6 months, 12 months

  2. Non-invasive Tear break-up time

    Non-invasive Tear break-up time (NIBUT) using MYAH's objective dry eye function - time after a blink (in seconds) for the first break in the tear film to be detected

    Measured: Baseline, 2 weeks, 3 months, 6 months, 12 months

  3. Ocular Protection Index

    Non-invasive breakup time secondary outcome measure divided by the average blink interval (number of blinks observed in a 60s period)

    Measured: Baseline, 2 weeks, 3 months, 6 months, 12 months

  4. Corneal punctate spots

    Number of punctate spots observed on the cornea following instillation of fluorescein and illumination with a blue light source

    Measured: Baseline, 2 weeks, 3 months, 6 months, 12 months

  5. Conjunctival punctate spots

    Number of puntate spots observed over the bulbar conjunctiva following instillation of lissamine green dye

    Measured: Baseline, 2 weeks, 3 months, 6 months, 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Apr 2026
  2. Study start21 Mar 2026
  3. Primary completion30 Apr 2027 (estimated)
  4. Study completion30 May 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Model description
Contralateral eye study, randomised
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
66 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07535749
Sponsor's protocol ID
Myopia-Control Contact Lenses
Status last verified
Sep 2026
First submitted
24 Mar 2026
Last updated
4 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Patients have not given permission for this

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing MiSight Contact Lenses (CooperVision) and Albiliti 1-Day (Johnson and Johnson, VisionCare) in people with Myopia Progression, run by Aston University at 1 site in New Zealand.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 4 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in New Zealand. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Mean Spherical Equivalent Cycloplegic Refraction (time frame: Baseline, 2 weeks, 3 months, 6 months, 12 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Sep 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in